Patents by Inventor Shigeyuki Tasaka

Shigeyuki Tasaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6306853
    Abstract: A 1,4-dihydropyridine derivative having the formula (I): wherein, R1 represents a substituted or unsubstituted phenyl or pyridyl group, R2 represents a C1 to C5 lower alkyl group, R3 represents a substituted or unsubstituted C1 to C8 alkyl, alkenyl, alkynyl or substituted or unsubstituted C3 to C7 cycloalkyl or cycloalkenyl group, R4 represents —A—R5, wherein A represents a C3 to C5 alkynylene group having one triple bond, and R5 represents a substituted or unsubstituted pyridyl, quinolyl, isoquinolyl or pyrimidyl group and a drug for overcoming resistance to an anti-cancer drug or a drug increasing the effect of an anti-cancer drug containing as an effective ingredient the derivative or its pharmacologically acceptable salt or hydrate.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: October 23, 2001
    Assignee: Nikken Chemicals Co., Ltd.
    Inventors: Shigeyuki Tasaka, Akira Kiue, Hiromasa Omori, Hirokazu Tanabe, Noriaki Gomi
  • Patent number: 5919799
    Abstract: An imidazothiazole compound having the formula (A): ##STR1## wherein R.sub.1 is a phenyl or napthyl which may have a substituent, R.sub.2 is an acyl, and the two bonds at dotted line portions may or may not exist simultaneously, or a pharmacologically acceptable salt thereof and an agent for overcoming resistance to an anti-neoplastic agent or an enhancer for the effect of an anti-neoplastic agent comprising said compound or a pharmacologically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: July 6, 1999
    Assignee: Nikken Chemicals Co., Ltd.
    Inventors: Shigeyuki Tasaka, Akira Kiue
  • Patent number: 5843950
    Abstract: A 1,4-dihydropyridine compound having the formula (I): ##STR1## wherein, R.sup.1 indicates --COO--A--(3-pyridyl), A indicates a C.sub.3 -C.sub.6 straight chain alkylene group in which one piperazine may be interposed; R.sup.2 indicates a C.sub.2 -C.sub.10 alkyl group, alkenyl group or alkynyl group; a lower alkyl group or lower alkenyl group having a substituent; or a cycloalkyl group which may have a substituent; R.sup.3 indicates the same group as R.sup.1 or --COO--R.sup.4 ; and R.sup.4 indicates a lower alkyl group which may have a substituent or its pharmacologically acceptable salt and an anti-allergenic drug, antiphlogistic, drug for overcoming resistance to anti-cancer drugs, or drug for reinforcing the effect of anti-cancer drugs containing the same as effective ingredients.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: December 1, 1998
    Assignee: Nikken Chemicals Co., Ltd.
    Inventors: Shigeyuki Tasaka, Teruhisa Miura, Akira Kiue, Taketsugu Seki, Tetsuro Sano, Mie Kamakura, Masakazu Fujita
  • Patent number: 4968708
    Abstract: The present invention relates to novel imidazo-[2,1-b]benzothiazole compounds represented by formula (I) and pharmacological acceptable salts thereof: ##STR1## wherein R.sub.1 represents a hydrogen atom or a lower alkyl group having 1 to 4 carbon atoms; R.sub.2 represents a ##STR2## group (wherein X and Y, which may be the same or different, each represents a hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms or a substituted or unsubstituted phenyl group), a --CH.sub.2 --O--Z group (wherein Z represents a lower alkyl group having 1 to 4 carbon atoms or a substituted or unsubstituted benzyl group) or a --CH.sub.2 --O--CO--W group (wherein W represents an alkyl group having 1 to 8 carbon atoms, an alkylamino group having 1 to 8 carbon atoms, a substituted or unsubstituted phenyl group or a thienyl group); and R.sub.3 ; R.sub.4 and R.sub.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: November 6, 1990
    Assignee: Nikken Chemicals Co., Ltd.
    Inventors: Taketsugu Seki, Shigeyuki Tasaka, Ryuichi Hoshino